Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 0.66 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.60 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.60 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31289136 | 1.00 | EGFR (0.66) | EGFRERBB2ERBB3ERBB4 | |
| SCHEMBL17385141 | 0.93 | EGFR (0.63) | EGFRERBB2ERBB3ERBB4 | |
| SCHEMBL30748688 | 0.93 | EGFR (0.63) | EGFRERBB2ERBB3ERBB4 | |
| SCHEMBL29146006 | 0.92 | EGFR (0.56) | EGFRERBB2ERBB3ERBB4 | |
| SCHEMBL24464114 | 0.92 | EGFR (0.55) | EGFRERBB2ERBB3ERBB4 | |
| SCHEMBL19103269 | 0.91 | EGFR (0.57) | EGFRERBB2ERBB3ERBB4 | |
| SCHEMBL19103257 | 0.91 | EGFR (0.54) | EGFRERBB2ERBB3ERBB4 | |
| SCHEMBL28839358 | 0.91 | EGFR (0.57) | EGFRERBB2ERBB3ERBB4 | |
| SCHEMBL17384784 | 0.90 | EGFR (0.66) | EGFRERBB2ERBB3ERBB4 | |
| SCHEMBL24771072 | 0.90 | EGFR (0.53) | EGFRERBB2ERBB3ERBB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12084431-B2 | Pharmaceutical salts of pyrimidine derivatives and method of treating disorders | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-09-10 | — | — | US | disclosed |
| EP-4234547-A2 | PHARMACEUTICAL SALTS OF PYRIMIDINE DERIVATIVES AND METHOD OF TREATING DISORDERS | Takeda Pharmaceutical Company Limited (JP) | 2023-08-30 | — | — | EP | disclosed |
| US-20230150975-A1 | COMPOUNDS USED AS KINASE INHIBITORS AND APPLICATION THEREOF | TYK MEDICINES (ZHENGZHOU), INC. (CN) | 2023-05-18 | — | — | US | disclosed |
| US-20210309640-A1 | PHARMACEUTICAL SALTS OF PYRIMIDINE DERIVATIVES AND METHOD OF TREATING DISORDERS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-10-07 | — | — | US | disclosed |
| CN-112313223-A | Pharmaceutically acceptable salts of pyrimidine derivatives and methods of treating conditions | 阿瑞雅德制药公司 | 2021-02-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12084431-B2 | Pharmaceutical salts of pyrimidine derivatives and method of treating disorders | DPYD, TYMP, TYMS | EGFR 5/4885ERBB2 18/4885ERBB3 25/4885 |
| US-20210309640-A1 | PHARMACEUTICAL SALTS OF PYRIMIDINE DERIVATIVES AND METHOD OF TREATING DISORDERS | DPYD, TYMP, TYMS | EGFR 9/4885ERBB2 23/4885ERBB3 34/4885 |
| US-20230150975-A1 | COMPOUNDS USED AS KINASE INHIBITORS AND APPLICATION THEREOF | EGFR, ERBB2, ERBB3 | EGFR 1/4885ERBB2 2/4885ERBB3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.